Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Terminated 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Fallopian Tube Neoplasms 2Carcinoma, Ovarian Epithelial 2Small Cell Lung Carcinoma 1Sarcoma 1Neurofibrosarcoma 1Neoplasms 1Lung Cancer - Malignant Pleural Mesothelioma 1Leukemia, Myeloid, Acute 1Leukemia 1Disorders of Sex Development 1

Interventions

Carboplatin 16Paclitaxel 9Cyclophosphamide 8liposomal doxorubicin 6Peripheral Blood Stem Cell Transplantation 6Topotecan 5Filgrastim 5pembrolizumab 4Docetaxel 4oregovomab 3veliparib 2sacituzumab govitecan 2epacadostat 2avelumab 2Thiotepa 2Taxes 2STA 9090 2Nivolumab 2Erlotinib Hydrochloride 2Drug Therapy 2Cisplatin 2Amifostine 2talazoparib 1ribociclib 1relacorilant 1ralimetinib 1poly ICLC 1phenoxodiol 1peginterferon alfa-2b 1pegfilgrastim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Carcinoma, Ovarian Epithelial × STA 9090 × Clear all
NCT01962948 2024-03-26

Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Fox Chase Cancer Center

Phase 1/2 Terminated
12 enrolled 8 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT02012192 2019-08-13

GANNET53: Ganetespib in Metastatic, p53-mutant, Platinum-resistant Ovarian Cancer

Medical University Innsbruck

Phase 1/2 Terminated
133 enrolled 10 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Disorders of Sex Development

Data powered by HemOnc (CC BY 4.0) Colophon âš¡